Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials

Marc D. Ryser, Roman Gulati, Marisa C. Eisenberg, Yu Shen, E. Shelley Hwang, Ruth Etzioni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

It is generally accepted that some screen-detected breast cancers are overdiagnosed and would not progress to symptomatic cancer if left untreated. However, precise estimates of the fraction of nonprogressive cancers remain elusive. In recognition of the weaknesses of overdiagnosis estimation methods based on excess incidence, there is a need for model-based approaches that accommodate nonprogressive lesions. Here, we present an in-depth analysis of a generalized model of breast cancer natural history that allows for a mixture of progressive and indolent lesions. We provide a formal proof of global structural identifiability of the model and use simulation to identify conditions that allow for parameter estimates that are sufficiently precise and practically actionable. We show that clinical follow-up after the last screening can play a critical role in ensuring adequately precise identification of the fraction of indolent cancers in a stop-screen trial design, and we demonstrate that model misspecification can lead to substantially biased estimates of mean sojourn time. Finally, we illustrate our findings using the example of Canadian National Breast Screening Study 2 (1980-1985) and show that the fraction of indolent cancers is not precisely identifiable. Our findings provide the foundation for extended models that account for both in situ and invasive lesions.

Original languageEnglish (US)
Pages (from-to)197-205
Number of pages9
JournalAmerican journal of epidemiology
Volume188
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Early Detection of Cancer
Breast Neoplasms
Neoplasms
Structural Models
Natural History
Breast
Medical Overuse
Incidence

ASJC Scopus subject areas

  • Epidemiology

Cite this

Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. / Ryser, Marc D.; Gulati, Roman; Eisenberg, Marisa C.; Shen, Yu; Hwang, E. Shelley; Etzioni, Ruth.

In: American journal of epidemiology, Vol. 188, No. 1, 01.01.2019, p. 197-205.

Research output: Contribution to journalArticle

Ryser, Marc D. ; Gulati, Roman ; Eisenberg, Marisa C. ; Shen, Yu ; Hwang, E. Shelley ; Etzioni, Ruth. / Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. In: American journal of epidemiology. 2019 ; Vol. 188, No. 1. pp. 197-205.
@article{38b53cba552e4d63b8dcbed1c4f75da8,
title = "Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials",
abstract = "It is generally accepted that some screen-detected breast cancers are overdiagnosed and would not progress to symptomatic cancer if left untreated. However, precise estimates of the fraction of nonprogressive cancers remain elusive. In recognition of the weaknesses of overdiagnosis estimation methods based on excess incidence, there is a need for model-based approaches that accommodate nonprogressive lesions. Here, we present an in-depth analysis of a generalized model of breast cancer natural history that allows for a mixture of progressive and indolent lesions. We provide a formal proof of global structural identifiability of the model and use simulation to identify conditions that allow for parameter estimates that are sufficiently precise and practically actionable. We show that clinical follow-up after the last screening can play a critical role in ensuring adequately precise identification of the fraction of indolent cancers in a stop-screen trial design, and we demonstrate that model misspecification can lead to substantially biased estimates of mean sojourn time. Finally, we illustrate our findings using the example of Canadian National Breast Screening Study 2 (1980-1985) and show that the fraction of indolent cancers is not precisely identifiable. Our findings provide the foundation for extended models that account for both in situ and invasive lesions.",
author = "Ryser, {Marc D.} and Roman Gulati and Eisenberg, {Marisa C.} and Yu Shen and Hwang, {E. Shelley} and Ruth Etzioni",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/aje/kwy214",
language = "English (US)",
volume = "188",
pages = "197--205",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials

AU - Ryser, Marc D.

AU - Gulati, Roman

AU - Eisenberg, Marisa C.

AU - Shen, Yu

AU - Hwang, E. Shelley

AU - Etzioni, Ruth

PY - 2019/1/1

Y1 - 2019/1/1

N2 - It is generally accepted that some screen-detected breast cancers are overdiagnosed and would not progress to symptomatic cancer if left untreated. However, precise estimates of the fraction of nonprogressive cancers remain elusive. In recognition of the weaknesses of overdiagnosis estimation methods based on excess incidence, there is a need for model-based approaches that accommodate nonprogressive lesions. Here, we present an in-depth analysis of a generalized model of breast cancer natural history that allows for a mixture of progressive and indolent lesions. We provide a formal proof of global structural identifiability of the model and use simulation to identify conditions that allow for parameter estimates that are sufficiently precise and practically actionable. We show that clinical follow-up after the last screening can play a critical role in ensuring adequately precise identification of the fraction of indolent cancers in a stop-screen trial design, and we demonstrate that model misspecification can lead to substantially biased estimates of mean sojourn time. Finally, we illustrate our findings using the example of Canadian National Breast Screening Study 2 (1980-1985) and show that the fraction of indolent cancers is not precisely identifiable. Our findings provide the foundation for extended models that account for both in situ and invasive lesions.

AB - It is generally accepted that some screen-detected breast cancers are overdiagnosed and would not progress to symptomatic cancer if left untreated. However, precise estimates of the fraction of nonprogressive cancers remain elusive. In recognition of the weaknesses of overdiagnosis estimation methods based on excess incidence, there is a need for model-based approaches that accommodate nonprogressive lesions. Here, we present an in-depth analysis of a generalized model of breast cancer natural history that allows for a mixture of progressive and indolent lesions. We provide a formal proof of global structural identifiability of the model and use simulation to identify conditions that allow for parameter estimates that are sufficiently precise and practically actionable. We show that clinical follow-up after the last screening can play a critical role in ensuring adequately precise identification of the fraction of indolent cancers in a stop-screen trial design, and we demonstrate that model misspecification can lead to substantially biased estimates of mean sojourn time. Finally, we illustrate our findings using the example of Canadian National Breast Screening Study 2 (1980-1985) and show that the fraction of indolent cancers is not precisely identifiable. Our findings provide the foundation for extended models that account for both in situ and invasive lesions.

UR - http://www.scopus.com/inward/record.url?scp=85059494792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059494792&partnerID=8YFLogxK

U2 - 10.1093/aje/kwy214

DO - 10.1093/aje/kwy214

M3 - Article

C2 - 30325415

AN - SCOPUS:85059494792

VL - 188

SP - 197

EP - 205

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 1

ER -